Harmony Biosciences Holdings (HRMY) Liabilities and Shareholders Equity (2019 - 2026)

Harmony Biosciences Holdings has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $1.3 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.3 billion, up 20.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 billion (up 26.51% YoY), and the FY2025 annual result was $1.3 billion, up 27.26% from the prior year.
• Liabilities and Shareholders Equity came in at $1.3 billion for Q1 2026 at Harmony Biosciences Holdings, roughly flat from $1.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.3 billion in Q1 2026 to a low of $464.0 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $847.0 million (2024), against an average of $876.4 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 64.53% in 2022 and increased 12.92% in 2024, its largest moves.
• Harmony Biosciences Holdings' Liabilities and Shareholders Equity stood at $673.9 million in 2022, then advanced by 20.42% to $811.4 million in 2023, then grew by 23.14% to $999.2 million in 2024, then increased by 27.26% to $1.3 billion in 2025, then increased by 0.02% to $1.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.